Unknown

Dataset Information

0

Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice.


ABSTRACT:

Purpose

TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concentrations as a pharmacodynamic (PD) readout was established in mice.

Methods

PK, TO and PD time-profiles were obtained in mice and analyzed by mechanistic binding kinetics model connected with an indirect response model in a step wise fashion. Brain distribution was investigated to elucidate a possible mechanism driving the hysteresis between PK and TO.

Results

The observed nonlinear PK/TO/PD relationship was well captured by mechanistic modeling framework within a wide dose range of TAK-831 in mice. Remarkably different brain distribution was observed between target and reference regions, suggesting that the target-mediated slow binding kinetics rather than slow penetration through the blood brain barrier caused the observed distinct kinetics between PK and TO.

Conclusion

A quantitative mechanistic model for concentration- and time-dependent nonlinear PK/TO/PD relationship was established for TAK-831 in mice with accounting for possible rate-determining process. The established mechanistic modeling framework will provide a quantitative means for multilayer biomarker-assisted clinical development in multiple central nervous system indications.

SUBMITTER: Yoneyama T 

PROVIDER: S-EPMC7478952 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice.

Yoneyama Tomoki T   Sato Sho S   Sykes Andy A   Fradley Rosa R   Stafford Stuart S   Bechar Shyam S   Howley Eimear E   Patel Toshal T   Tagawa Yoshihiko Y   Moriwaki Toshiya T   Asahi Satoru S  

Pharmaceutical research 20200805 8


<h4>Purpose</h4>TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concentrations as a pharmacodynamic (PD) readout was established in mice.<h4>Methods</h4>PK, TO and PD time-profiles were obtained in mice and analyzed by mechanistic binding kinetics model connected  ...[more]

Similar Datasets

| S-EPMC6561755 | biostudies-literature
| S-EPMC4366384 | biostudies-literature
| S-EPMC7319013 | biostudies-literature
| S-EPMC5063900 | biostudies-literature
| S-EPMC9290503 | biostudies-literature
| S-EPMC4816246 | biostudies-literature
| S-EPMC4560520 | biostudies-literature
| S-EPMC3318151 | biostudies-other
| S-EPMC3579253 | biostudies-literature
| 2300705 | ecrin-mdr-crc